Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Scilex Holding Company ( (SCLX) ) has provided an announcement.
Scilex Holding Company, through its subsidiary Semnur Pharmaceuticals, is involved in a merger agreement with Denali Capital Acquisition Corp. and Denali Merger Sub Inc. On July 22, 2025, Semnur entered into Amendment No. 2 to the Merger Agreement, modifying the definitions of the ‘Exchange Ratio’ and ‘Merger Consideration’ to allow for the issuance of additional shares of common stock prior to the closing of the Business Combination. This amendment aims to facilitate potential private placement financing and issuance to service providers, maintaining a 1.25-to-1 exchange ratio.
The most recent analyst rating on (SCLX) stock is a Buy with a $245.00 price target. To see the full list of analyst forecasts on Scilex Holding Company stock, see the SCLX Stock Forecast page.
More about Scilex Holding Company
Average Trading Volume: 142,149
Technical Sentiment Signal: Sell
Current Market Cap: $61.45M
See more data about SCLX stock on TipRanks’ Stock Analysis page.